Abrégé

Immunogenic compositions that include an adjuvant formed from nanoparticles of saponins combined with cholesterol and phospholipids have particular interactions with body tissue and immune cells. These interactions include increased immune response in the draining lymph node, strong activation of T and B cells in the lymph node, and rapid clearance of the saponin fraction while the cholesterol fraction remains in the system.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Abrégé

Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Produits et services

Vaccines. Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development.

Abrégé

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are immunogenic compositions comprising an antigen of a Plasmodium parasite. Methods of administering the aforementioned compositions are also disclosed.

Classes IPC  ?

• A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/29 - Virus de l'hépatite
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants

Abrégé

The present disclosure provides immunogenic compositions for inducing immune responses against malaria. The present disclosure also provides novel methods of administering said immunogenic compositions. Disclosed herein are methods and compositions for treating malaria by administering immunogenic compositions.

Classes IPC  ?

• A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are coronavirus (CoV) Spike(S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-COV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/12 - Antigènes viraux
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 9/51 - Nanocapsules

Abrégé

An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 μg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-COV-2, a heterogeneous SARS-COV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Disclosed herein are RSV F glycoproteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/12 - Antigènes viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention is directed to methods of purifying viral proteins for use in vaccine compositions. The method includes a capture step and a polish step. The capture step includes passing a solution containing a protein over a hydrophobic interaction chromatography column and eluting a crude protein eluate from the column. The polish step includes passing the crude protein eluate over a ligand affinity chromatography column and recovering a first flow through intermediate, passing the first flow through intermediate over an anion exchange chromatography column and recovering a second flow through intermediate, and passing the second flow through intermediate over another ligand affinity chromatography column and recovering a purified protein eluate. The present invention also provides a purified protein having a hydrophobic membrane domain that is produced by a baculovirus expression system in cultured insect cells, wherein the purified protein has a purity of greater than 85%.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• B01D 15/18 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives aux différents types d'écoulement
• B01D 15/32 - Chromatographie en phase liée, p. ex. avec une phase normale liée, une phase inverse ou une interaction hydrophobe
• B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
• B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
• C07K 1/18 - Chromatographie d'échange d'ions
• C07K 1/20 - Chromatographie de partage, de phase inverse ou d'interaction hydrophobe
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents

Abrégé

The present invention is directed to methods of purifying viral proteins for use in vaccine compositions. The method includes a capture step and a polish step. The capture step includes passing a solution containing a protein over a hydrophobic interaction chromatography column and eluting a crude protein eluate from the column. The polish step includes passing the crude protein eluate over a ligand affinity chromatography column and recovering a first flow through intermediate, passing the first flow through intermediate over an anion exchange chromatography column and recovering a second flow through intermediate, and passing the second flow through intermediate over another ligand affinity chromatography column and recovering a purified protein eluate. The present invention also provides a purified protein having a hydrophobic membrane domain that is produced by a baculovirus expression system in cultured insect cells, wherein the purified protein has a purity of greater than 85%.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 7/02 - Isolement ou purification

Abrégé

An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Produits et services

(1) Pharmaceutical preparations for the treatment of infectious diseases and vaccine preparations and vaccine adjuvants. (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines.

Abrégé

Provided herein are compositions comprising Epstein-Barr Virus envelope proteins (e.g., glycoprotein 350 (gp350)) and saponin adjuvant and methods of using the aforementioned compositions for inducing an immune response against Epstein-Barr Virus.

Classes IPC  ?

• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• A61K 39/12 - Antigènes viraux
• A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/107 - Émulsions
• A61K 39/12 - Antigènes viraux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides

Produits et services

Vaccines. Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development.

Produits et services

Vaccines. Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development.

Produits et services

Vaccines. Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development.

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present disclosure provides immunogenic compositions for inducing immune responses against malaria. The present disclosure also provides novel methods of administering said immunogenic compositions. Disclosed herein are methods and compositions for treating malaria by administering immunogenic compositions.

Classes IPC  ?

• C07K 14/445 - Plasmodium
• A61P 37/04 - Immunostimulants
• A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose

Produits et services

(1) Vaccines (1) Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Produits et services

(1) Vaccines (1) Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Produits et services

(1) Vaccines (1) Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Abrégé

Plasmodium Plasmodium parasite. Methods of administering the aforementioned compositions are also disclosed.

Classes IPC  ?

• A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
• A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
• C07K 14/445 - Plasmodium
• C12N 15/30 - Gènes codant pour des protéines protozoaires, p. ex. Plasmodium, Trypanosoma, Eiméria
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 39/12 - Antigènes viraux
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Produits et services

Vaccines

Produits et services

Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Produits et services

Vaccines

Produits et services

Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Produits et services

Vaccines

Abrégé

Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Abrégé

Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61K 9/51 - Nanocapsules

Abrégé

Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants for medical use. Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants. Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

Vaccines.

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants. Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Abrégé

C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Classes IPC  ?

• A61K 39/116 - Antigènes bactériens polyvalents
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques

Produits et services

Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

(1) Pharmaceutical preparations for the treatment of infectious diseases, namely, Covid-19, malaria, Ebola, influenza, and respiratory infections; human vaccines; vaccine adjuvants. (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

(1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

(1) Pharmaceutical preparations for the treatment of infectious diseases, namely, Covid-19, malaria, Ebola, influenza, and respiratory infections; human vaccines; vaccine adjuvants. (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Abrégé

The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants. Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

Vaccines for the treatment and prevention of Covid-19. Providing medical and scientific research information in the field of Covid-19 vaccines, and clinical trials and post-market trials related to Covid-19 vaccines; consulting services in the field of research and development of Covid-19 vaccines; Covid-19 vaccine research and development.

Produits et services

Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines

Produits et services

Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines

Produits et services

Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines

Produits et services

(1) Pharmaceutical preparations for the treatment of infectious diseases, namely, Covid-19, malaria, Ebola, influenza, and respiratory infections; human vaccines; vaccine adjuvants. (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines.

Produits et services

(1) Vaccines for the treatment and prevention of Covid-19 (1) Providing medical and scientific research information in the field of Covid-19 vaccines, and clinical trials and post-market trials related to Covid-19 vaccines; consulting services in the field of research and development of Covid-19 vaccines; Covid-19 vaccine research and development

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants for medical purposes

Produits et services

Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/12 - Antigènes viraux

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Produits et services

Vaccines for the treatment and prevention of Covid-19. Providing medical and scientific research information in the field of Covid-19 vaccines, and clinical trials and post-market trials related to Covid-19 vaccines; consulting services in the field of research and development of Covid-19 vaccines; Covid-19 vaccine research and development.

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases, biologic preparations for the treatment of infectious diseases, and vaccine preparations and vaccine adjuvants. Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines.

Abrégé

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

(1) Human vaccines; vaccine adjuvants; pharmaceutical preparations for the treatment of infectious diseases, namely, Covid-19, malaria, Ebola, influenza, and respiratory infections. (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines.

Produits et services

(1) Vaccines for human use (1) Providing medical and scientific research information in the field of vaccines, biomedicine, clinical trials and post-market trials; consulting services in the field of research and development of vaccines; vaccine research and development

Abrégé

The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 38/00 - Préparations médicinales contenant des peptides
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci

Produits et services

(1) Human vaccines

Abrégé

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/12 - Antigènes viraux
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Classes IPC  ?

• A61K 39/116 - Antigènes bactériens polyvalents
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/12 - Antigènes viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 9/107 - Émulsions
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61K 9/51 - Nanocapsules
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61P 37/04 - Immunostimulants
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens

Abrégé

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/12 - Antigènes viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 9/107 - Émulsions
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/51 - Nanocapsules
• A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 39/12 - Antigènes viraux
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/08 - Clostridium, p. ex. Clostridium tetani
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques

Abrégé

Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Classes IPC  ?

• A61K 39/08 - Clostridium, p. ex. Clostridium tetani
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques

Abrégé

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 39/12 - Antigènes viraux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

(1) Human vaccines

Abrégé

The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/205 - Rabdoviridae, p. ex. virus de la rage
• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

(1) Human vaccines; vaccine adjuvants (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines

Produits et services

(1) Human vaccines; vaccine adjuvants (1) Pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines